Navigation Links
Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available

ST. PETERSBURG, Fla., Oct. 14 /PRNewswire/ -- In the United States, a woman is diagnosed with breast cancer every three minutes, according to the American Cancer Society. Except for skin cancers, breast cancer is the most frequently diagnosed cancer among woman.

To help fight this disease, eMed-ID, the world's first emergency medical information device franchise, will donate $10 for every pink Personal Health Records (PHR) wristband sold to raise awareness during Breast Cancer Awareness Month. This pink wristband, as well as other optional styles, contains a USB device that has an individual's personal health history, medications taken, allergies, etc. eMed-ID's proprietary device is designed to expedite emergency responders' treatment of a patient who may not be able to communicate their personal medical information. It also helps consolidate health records and make them accessible to healthcare providers when needed.

"Individuals with breast cancer, as well as survivors of breast cancer, find themselves seeing numerous physicians and managing multiple medications and courses of treatment throughout their illness and beyond," said Lonnie Helgerson, CEO, eMed-ID Franchising, LLC. "As a result, we believe strongly that this group of individuals should have their personal health records consolidated and with them on e-Med-ID's PHR device in case of emergency or other circumstances that require medical history at the ready."

The eMed-ID package is $69.95 and includes the PHR USB device, four eMed-ID caregiver cards, two eMed-ID In Case of Emergency (I.C.E.) refrigerator cards and a bound report. In addition, eMed-ID is the only medical identification product that also provides customers with an optional legally-binding healthcare surrogate, HIPAA release and living will. The company also partners with the "Silver Alert" program, modeled after "Amber Alert," to help protect an increasing number of citizens with cognitive impairments. The pink wristband is just one option. Others include blue wristbands, credit cards and keychains.

"We are honored to join the fight on breast cancer and contribute a portion of the sales of our popular pink wristbands to breast cancer research," said Helgerson. "We've built the eMed-ID business to provide local communities, including people of all ages, with medical services and products that improve the quality of healthcare and save lives. This is just another way to become involved in the health care community and help individuals and families manage their own health."

Consumers can purchase the eMed-ID pink wristband, as well as other products, through eMed-ID's franchise network in cities located throughout the United States. To find your eMed-ID representative, visit or call 1-866-607-0411.

For those interested in starting their own business, eMed-ID represents an ideal franchise opportunity given the current economic conditions by providing interested franchisees a low-cost of entry. The company is offering candidates the opportunity with a total investment of less than $10,000. Three-year term financing is available to qualified candidates for approximately $38 a week.

Area Representative opportunities are available starting at $29,950 to those interested in recruiting franchisees and owning a minimum protected territory of 200,000 residents. In addition, the franchise provides Veterans a $2,450 discount and a three percent reduction on financing interest.

About eMed-ID

Headquartered in St. Petersburg, FL, eMed-ID is the world's first emergency medical device franchise currently with 22 franchisees operating in several states including Florida, Indiana, Texas, Oregon, Arizona, North Carolina and Montana. The home-based, low cost franchise offers consumers a suite of emergency medical devices to protect their family and friends. For additional product or franchising information, please call 866.607.0411 or log onto

    Media Contact:
    Kim Ryan
    Fish Consulting


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
(Date:10/12/2015)... 12, 2015 Device usage in healthcare continues ... integrate these devices into existing clinical workflow. In response, ... and mobility solutions, has launched the SV10 series of ... a wide array of laptops and tablets. In addition, ... exclusively for Microsoft Surface and is compatible with all ...
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)... Oct. 12, 2015 Indivior PLC (LON: INDV) today ... Delaware granted the Company,s motion to ... New Drug Application (ANDA) No. 205299 to market a generic ... naloxone) Sublingual Film (CIII) in the United States ... Since August 2013, Indivior has received Paragraph IV certifications from ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... ... on being awarded a contract with the U.S. Biomedical Advanced Research and Development ... development and procurement of its ReCell® Autologous Cell Harvesting Device under a U.S. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The translation for ARIS® 7.x ... migration of complete ARIS installations into the Microsoft world. The ARIS models will be ... Visio® is very familiar for both IT and Office users it is acknowledged as ...
(Date:10/12/2015)... ... October 12, 2015 , ... The ... to 8:00 pm at the Sheraton Philadelphia Hotel, 3549 Chestnut Street, Philadelphia, PA ... attending from across the country. All specialties will be represented. Attendees will enjoy ...
(Date:10/12/2015)... Greifensee, Switzerland (PRWEB) , ... October 12, 2015 ... ... of new product upgrades designed to streamline laboratory processes. In addition, METTLER TOLEDO ... a free Lean Lab Checklist to help improve productivity through the ...
(Date:10/12/2015)... ... ... On Sept. 26, the team at Dynamic Fitness joined supporters from 58 ... Houston Zoo during September's Childhood Cancer Awareness Month. The Walk/Run helped to raise funds ... up with the idea to involve his team with the walk in an effort ...
Breaking Medicine News(10 mins):